Cempra, Inc. (NASDAQ:CEMP) has been assigned an average recommendation of “Hold” from the twenty analysts that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating, eleven have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $8.85.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Cempra from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a research report on Friday, August 11th. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 target price on shares of Cempra in a research report on Thursday, August 10th. Roth Capital cut shares of Cempra from a “buy” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $4.00 in a research report on Thursday, August 10th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $3.00 target price on shares of Cempra in a research report on Thursday, September 14th.

Institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company boosted its stake in Cempra by 5.0% during the second quarter. The Manufacturers Life Insurance Company now owns 39,499 shares of the biotechnology company’s stock worth $182,000 after buying an additional 1,870 shares during the period. State Street Corp boosted its stake in Cempra by 7.9% during the second quarter. State Street Corp now owns 855,928 shares of the biotechnology company’s stock worth $3,936,000 after buying an additional 62,438 shares during the period. Numeric Investors LLC boosted its stake in Cempra by 2.9% during the second quarter. Numeric Investors LLC now owns 284,900 shares of the biotechnology company’s stock worth $1,311,000 after buying an additional 7,900 shares during the period. Voya Investment Management LLC boosted its stake in Cempra by 34.1% during the second quarter. Voya Investment Management LLC now owns 23,006 shares of the biotechnology company’s stock worth $106,000 after buying an additional 5,848 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Cempra by 1,279.1% during the second quarter. Dimensional Fund Advisors LP now owns 753,402 shares of the biotechnology company’s stock worth $3,466,000 after buying an additional 698,771 shares during the period. Hedge funds and other institutional investors own 49.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Cempra, Inc. (CEMP) Receives Average Recommendation of “Hold” from Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/11/cempra-inc-cemp-receives-average-recommendation-of-hold-from-analysts.html.

Cempra (NASDAQ:CEMP) opened at 3.20 on Wednesday. The stock’s market capitalization is $168.02 million. The firm has a 50 day moving average of $3.09 and a 200-day moving average of $3.73. Cempra has a 52 week low of $2.55 and a 52 week high of $24.48.

Cempra (NASDAQ:CEMP) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.09. The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $3.58 million. Cempra had a negative net margin of 560.40% and a negative return on equity of 53.99%. The company’s quarterly revenue was down 74.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.51) earnings per share. On average, equities analysts predict that Cempra will post ($1.01) EPS for the current year.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.